Humacyte ( (HUMA) ) has shared an update.
On March 27, 2025, Humacyte, Inc. responded to a New York Times article questioning the FDA’s approval process for their product, Symvess. The company clarified that the FDA conducted a thorough review, including consultations with external experts, before approving Symvess for treating vascular trauma. Humacyte emphasized their commitment to safety and effectiveness, citing successful outcomes in trials and ongoing post-approval studies. The company also addressed inaccuracies in the article, defending the product’s use in battlefield injuries and highlighting their humanitarian efforts in Ukraine.
More about Humacyte
Humacyte, Inc. operates in the biotechnology industry, focusing on the development of bioengineered human tissue-based products. The company’s primary product, Symvess, is designed for use in vascular trauma repair, particularly in situations where autologous vein grafting is not feasible.
YTD Price Performance: -61.39%
Average Trading Volume: 2,762,456
Technical Sentiment Signal: Buy
Current Market Cap: $257.3M
For detailed information about HUMA stock, go to TipRanks’ Stock Analysis page.